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?
1. C6 glioma 세포에서 재조합 아데노 바이러스의 감염 효
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Uninfected MOI=100 MOI=200 MOI=500 
Fig. 2. The expression of CD/TK in C6 glioma or 293 cells. The
cells were infected with ad-CD/TK at designated MOIs and
the equal amount of proteins was subjected to 6% SDS-PAGE.
The CD/TK fusion proteins were visualized by immunoblotting
analysis with monoclonal antibody to TK. The position of fusion
protein CD/TK was indicated by arrow. 
 
Fig. 1. The transduction efficiency 
of recombinant adenovirus ion C6 
glioma cells. Transduction efficien-
cy was determined by examining 
expression of ?-galactosidase 
?LacZ? after infecting the cells with 
ad-?-galactosidase. Dark staining 
represented successful ?-galac-
tosidase gene expression in the 
cells. The expression of ?-galac-
tosidase in cultured C6 glioma 
cells. The cells were infected with 
ad-?-galactosidase at MOI of 100, 
200 or 500 and then stained with 
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Fig. 3. In vitro cytotoxicity of ad-CD/TK combined with GCV or 5-FC treatment in C6 glioma cells. The cells infected with ad-CD/TK 
were exposed to GCV or 5-FC alone or in combined treatments after plating into 96 wells. The cell survival rate was determined 
by crystal violet staining Six days after infection. The mean values of at least three independent experiments are represented and 
standard errors are represented by error bars. A?Sensitivity to GCV of the cells transduced with ad-CD/TK. The cells were 
infected with ad-CD/TK at MOI of 100??? or 200???. As a control group, the cells were mock-infected??? or infected with ad-?
E1 at MOI of 200???. B?Sensitivity to 5-FC of the cells transduced with ad-CD/TK. The data were represented as Fig. 3A. 
C?Additive effect of GCV and 5-FC treatment. The cells were treated with 5-FC of 10g/ml?? ? ?, GCV of 0.1g/ml?? ? ? or both?? ? ? 
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